Skip to content
OpenCapital
Get started

Ionis Pharmaceuticals IONS AFS and Trading Securities - Unrealized Loss Position (>=12 Months) Fair Value

AFS and Trading Securities - Unrealized Loss Position (>=12 Months) Fair Value at other companies

Exelixis logo
ExelixisEXEL
——

Other financials

Income statement

See full
Revenue$246.1M+87.0%
Gross profit$243.1M+86.8%
Operating income-$117.4M+20.0%
Net income-$92.5M+37.0%
EPS (diluted)-$0.56+39.8%

Balance sheet

See full
Cash & equivalents$173.4M-34.4%
Total debt$691.7M+334%
Total equity$491.4M+3.3%
Total assets$3.4B+22.6%

Cash flow

See full
Operating cash flow-$792.8M-426%
CapEx$21.8M+73.0%
Free cash flow-$814.6M-399%

Valuation

See full
Market cap$12.25B+159%
Enterprise value$12.77B+175%
P/S11.6×+5.0×

Profitability

See full
Gross margin98.4%-0.2pp
Operating margin-33.3%-11.0pp
Net margin-30.9%-10.5pp
FCF margin-77.4%+35.3pp

Returns & leverage

See full
Return on equity-67.6%-20.3pp
Debt / equity1.4×+1.1×
Current ratio4.1×-5.6×

Where this comes from

Reported directly by Ionis Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger.

The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ionis Pharmaceuticals's afs and trading securities - unrealized loss position (>=12 months) fair value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ionis Pharmaceuticals's AFS and trading securities - unrealized loss position (>=12 months) fair value?
Ionis Pharmaceuticals (IONS) reported AFS and trading securities - unrealized loss position (>=12 months) fair value of $11.32M in Q1 2026.
How has Ionis Pharmaceuticals's AFS and trading securities - unrealized loss position (>=12 months) fair value changed year-over-year?
Ionis Pharmaceuticals's AFS and trading securities - unrealized loss position (>=12 months) fair value decreased by 50.5% year-over-year, from $22.88M to $11.32M.